 Home > Active Ingredient News > Antitumor Therapy > JCO: Phase 3 trial at Peking University Cancer Hospital reveals the clinical benefits of multi-departmental combined treatment of metastatic stomach cancer

JCO: Phase 3 trial at Peking University Cancer Hospital reveals the clinical benefits of multi-departmental combined treatment of metastatic stomach cancer

 Last Update: 2021-01-23
 Source: Internet
 Author: User

Tags

metabolic therapy

1 4 cyclohexadiene

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Gastroesophageal cancer (EGC) is the second leading cause of cancer-related death among the world.
, effective interventions are urgently needed to improve the prognostics of metastasis EGC patients.
study assessed the impact of early interdisciplinary support therapy integration on overall survival rate (OS) in metastasis EGC patients.
This is an open randomized controlled phase 3 trial conducted at Peking University Cancer Hospital, which recruited previously untreated metastasis EGC patients to be randomized to the Early Interdisciplinary Support Therapy Joint Standard Therapy (ESC) or Standard Treatment (EC) group at 2:1.
patients in the ESC group were treated by gastroenterologists, oncologists, dietitians and psychologists;
end point is OS.
16 April 2015 - 29 December 2017, a total of 328 patients were recruited: 214 in the ESC group and 114 in the SC group.
as of January 26, 2019, 15 (5%) patients had lost their visits.
of first-line chemotherapy in the main prognosmed ESC group was 5 (IQR 4-7) and 4 in the SC group (IQR 2-6).
14.8 months (95% CI 13.3-16.3) and 11.9 months (9.6-13.6; HR 0.68, 95% CI 0.51-0.9; P=0.021）。
group prognostic study showed that early integration of interdisciplinary support therapy increased the survival benefits of metastatic gastric cancer patients.
future is worth further optimization and standardization research exploration.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.